## 16.1.5 Signatures of Principal or Coordinating Investigator(s) and Sponsor's Responsible Medical Officer, Depending on the Regulatory Authority's Requirement, and Signature of Responsible Biostatistician

**STUDY TITLE:** A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled

Study to Evaluate the Efficacy, Safety, and Immunogenicity of

mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

**STUDY NUMBER:** mRNA-1273-P301

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

**SPONSOR'S SIGNATORY:** Allison August, MD

VP, Clinical Development, Infectious Diseases

ModernaTX, Inc.

	See esignature and date signed on	
SIGNATURE:	last page of document.	
	Allison August, MD	Date

**RESPONSIBLE BIOSTATISTICIAN:** Honghong Zhou, PhD

Senior Director, Biostatistics

ModernaTX, Inc.

See esignature and date signed on
last page of document.

Honghong Zhou, PhD

Date

**CLIENT:** ModernaTX, Inc.

**SIGNATURE:** 

200 Technology Square Cambridge, MA 02139

**United States** 

## Signature Page for VV-CLIN-002715 v1.0

•	Honghong Zhou Clinical 07-Aug-2021 11:19:30 GMT+0000
Approval	Allison August Medical 09-Aug-2021 21:43:40 GMT+0000

Signature Page for VV-CLIN-002715 v1.0